3,949 results on '"Curigliano, A."'
Search Results
2. Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy
3. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
4. Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study
5. Comment on “Reply: Comment on BIA-ALCL: Comparing the Risk Profiles of Smooth and Textured Breast Implants”
6. Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study
7. Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study
8. Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer
9. Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
10. Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
11. Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy
12. Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer
13. Contributors
14. Machine learning in computational pathology through self-supervised learning and vision transformers
15. Artificial intelligence in small-molecule drug discovery
16. Artificial intelligence in cancer research and precision medicine
17. Artificial intelligence in the oncology workflow: Applications, limitations, and future perspectives
18. AI/ML and drug repurposing in lung cancer: State of the art and potential roles for retinoids
19. Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study
20. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
21. 'Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper'
22. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
23. A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
24. Hypoalbuminemia and Risk of Portal Vein Thrombosis in Cirrhosis
25. Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial
26. The evolving value assessment of cancer therapies: Results from a modified Delphi study
27. Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer
28. Global Landscape of the Attack of Predatory Journals in Oncology
29. Circulating tumor DNA in patients with locally advanced rectal cancer treated with multimodal treatment
30. Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched studyResearch in context
31. Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer
32. Fast Mimicking Diets and Other Innovative Nutritional Interventions to Treat Patients with Breast Cancer
33. Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
34. Antibody–Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer
35. Screening Programs for Breast Cancer: Toward Individualized, Risk-Adapted Strategies of Early Detection
36. Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?
37. Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer
38. New Concepts in Cardio-Oncology
39. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
40. Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
41. Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study
42. Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study
43. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
44. A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies
45. “Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper”
46. Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials
47. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
48. Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer
49. The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer
50. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.